Trial Profile
Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Feb 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 29 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.